The BreastCancer Trials of OraL EveROlimus-2 (BOLERO-2) (Baselgaet al. 2012), combined everolimus and exemestane for women withadvanced ER-positive/HER2-negative breast cancer who previously failed AI therapy. Here, ERBB2 is linked to breast carcinoma.